We are nibbling on this drug stock amid the broad market sell-off

David Rex, CEO of Eli Lilly

Scott Millian | CNBC

(This article was first sent to CNBC Investing Club members with Jim Cramer. For real-time updates in your inbox, Subscribe here.)

Shortly before the closing bell, we will buy 25 shares of Eli Lilly (LLY) Priced at approximately $243.81. After the trade, the Charitable Trust will own 400 shares of Eli Lilly. This purchase will increase Eli Lilly’s weight in the portfolio from approximately 2.28% to 2.43%.

Having avoided the temptation to push for stocks yesterday, we will be making one small buy on Friday afternoon because we believe you should hold your nose and pick something to accept when the broader market is hit hard as it is today. We go with Eli Lilly today as we look at stocks now down ~11% from their 52-week high as an opportunity to expand deeper into this relatively newer position.

We believe Eli Lilly is one of the best managed companies in the pharmaceutical industry with its diabetes focused portfolio continually achieving growth without any significant loss of exclusivity risk. Eli Lilly also has a proven track record of expanding margins.

But what interests us most in this story is the company’s pipeline. More specifically, Eli Lilly is developing two assets that CEO David Ricks previously called “two of the most valuable projects we’ve ever worked on and perhaps the most valuable projects in the industry right now.”

The two projects that Rex has indicated are donanemab as a treatment for Alzheimer’s disease and tirzepatide in type 2 diabetes and obesity. We believe that both drugs will be approved by the Food and Drug Administration next year and represent tremendous long-term opportunities that will support industry-leading growth for years to come.

Back on November 18 at the start of their coverage of Eli Lilly, analysts at BMO Capital described donanemab as a potential $10 billion opportunity if access hurdles can be overcome. And in an October research note from JPMorgan, analysts estimated that tirzepatide could be worth more than $10 billion in type 2 diabetes with an obesity potential in the billions.

The CNBC Investing Club is now the official headquarters of the Charitable Trust. It’s where you can see every step we take for the portfolio and get my view of the market before anyone else. The Charitable Trust and my writing are no longer affiliated with Action Alerts Plus in any way.

As a CNBC Investing Club subscriber with Jim Cramer, you will receive a trade alert before Jim places the trade. Jim usually waits 45 minutes after sending a trading alert before buying or selling a stock in his charitable trust fund portfolio. If the trade alert is sent before entering the market, Jim waits 5 minutes after the market opens before executing the trade. If the trade alert is issued less than 45 minutes on the trading day, Jim will execute the trade 5 minutes before the market closes. If Jim talks about a stock on CNBC TV, he waits 72 hours after the trade alert is issued before executing the trade. See here for an investment disclaimer.

(Long-time Jim Kramer Charitable Trust LLY.)


best of the web (1)

Related posts

Nasdaq rebounds from correction, Travelers jumps

The United States is in a period when “fixed assets are significantly outperforming,&#8221…
Read more

Why Netflix is raising prices

The company boosted subscriber costs on Friday, a move that raised its share price and raised…
Read more

Asian shares break losing streak as China cuts key mortgage rate

A man wearing a protective face mask, after the outbreak of the coronavirus, talks on his mobile…
Read more
Become a Trendsetter
Sign up for Davenport’s Daily Digest and get the best of Davenport, tailored for you.

Leave a Reply

Your email address will not be published. Required fields are marked *